TuHURA Biosciences (NASDAQ:HURA – Free Report) – Stock analysts at HC Wainwright raised their Q2 2026 EPS estimates for shares of TuHURA Biosciences in a research report issued on Thursday, April 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock.
HURA has been the topic of several other research reports. Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th.
TuHURA Biosciences Trading Up 3.0 %
Shares of NASDAQ HURA opened at $3.75 on Monday. The business has a 50 day simple moving average of $3.37. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $7.93.
Institutional Trading of TuHURA Biosciences
A number of institutional investors have recently modified their holdings of the business. Apollon Wealth Management LLC purchased a new stake in shares of TuHURA Biosciences during the fourth quarter worth $253,000. Suncoast Equity Management purchased a new stake in TuHURA Biosciences during the 4th quarter worth about $421,000. Charles Schwab Investment Management Inc. bought a new position in TuHURA Biosciences in the 4th quarter worth about $61,000. Accent Capital Management LLC purchased a new position in TuHURA Biosciences during the 4th quarter valued at about $29,000. Finally, Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the fourth quarter valued at about $1,084,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
- Five stocks we like better than TuHURA Biosciences
- How to Invest in Blue Chip Stocks
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- What is a Secondary Public Offering? What Investors Need to Know
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
